BR122021026889A2 - - Google Patents
Info
- Publication number
- BR122021026889A2 BR122021026889A2 BR122021026889A BR122021026889A BR122021026889A2 BR 122021026889 A2 BR122021026889 A2 BR 122021026889A2 BR 122021026889 A BR122021026889 A BR 122021026889A BR 122021026889 A BR122021026889 A BR 122021026889A BR 122021026889 A2 BR122021026889 A2 BR 122021026889A2
- Authority
- BR
- Brazil
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427686P | 2016-11-29 | 2016-11-29 | |
| US201762546390P | 2017-08-16 | 2017-08-16 | |
| PCT/US2017/063517 WO2018102315A1 (en) | 2016-11-29 | 2017-11-28 | Polymoprhs of sepiapterin and salts thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR122021026889A2 true BR122021026889A2 (OSRAM) | 2019-08-27 |
| BR122021026889A8 BR122021026889A8 (pt) | 2022-11-22 |
Family
ID=62241930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR122021026889A BR122021026889A8 (pt) | 2016-11-29 | 2017-11-28 | Formas cristalinas de base livre de sepiapterina e de sais dos mesmos, seu método de preparação, composições que as compreendem, uso dos mesmos e método de preparação de uma formulação líquida |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US11072614B2 (OSRAM) |
| EP (1) | EP3548497A4 (OSRAM) |
| JP (3) | JP7148533B2 (OSRAM) |
| KR (3) | KR102561697B1 (OSRAM) |
| CN (2) | CN110248948B (OSRAM) |
| AU (3) | AU2017366879C1 (OSRAM) |
| BR (1) | BR122021026889A8 (OSRAM) |
| CA (1) | CA3043502A1 (OSRAM) |
| CO (1) | CO2019006018A2 (OSRAM) |
| IL (2) | IL301470A (OSRAM) |
| MA (1) | MA46973A (OSRAM) |
| MX (3) | MX386520B (OSRAM) |
| WO (1) | WO2018102315A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| KR102561697B1 (ko) * | 2016-11-29 | 2023-07-28 | 피티씨 테라퓨틱스 엠피, 인크. | 세피아프테린의 다형체 및 그의 염 |
| MX2020002271A (es) * | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CN112654356A (zh) * | 2018-05-30 | 2021-04-13 | Ptc医疗Mp公司 | 增加四氢生物蝶呤血浆暴露的组合物和方法 |
| SMT202400430T1 (it) | 2018-05-30 | 2024-11-15 | Ptc Therapeutics Mp Inc | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina |
| BR112020024332A2 (pt) * | 2018-05-30 | 2021-02-23 | Ptc Therapeutics Mp, Inc. | sais farmaceuticamente aceitáveis de sepiapterina |
| ES2994060T3 (en) | 2019-08-05 | 2025-01-16 | Ptc Therapeutics Mp Inc | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| PT4034122T (pt) * | 2019-09-25 | 2025-09-18 | Ptc Therapeutics Mp Inc | Métodos de tratamento de hiperfenilalaninemia |
| CA3165636A1 (en) | 2020-01-24 | 2021-07-29 | Neil Smith | Methods for treating parkinson's disease with sepiapterin |
| EP4291196A1 (en) | 2021-02-09 | 2023-12-20 | PTC Therapeutics MP, Inc. | Methods for treating covid-19 with sepiapterin |
| US20240115572A1 (en) | 2021-02-09 | 2024-04-11 | Ptc Therapeutics Mp, Inc. | Methods for treating glioblastomas with sepiapterin |
| AU2022354887A1 (en) | 2021-09-29 | 2024-04-04 | Ptc Therapeutics, Inc. | Pharmaceutical composition of sepiapterin |
| WO2024249602A2 (en) * | 2023-05-30 | 2024-12-05 | The Board Of Trustees Of The Leland Stanford Junior University | Restless leg syndrome (rls) and periodic leg movements (plms) during sleep: biomarker and drug target |
| CN117205164B (zh) * | 2023-09-30 | 2024-07-26 | 山东新时代药业有限公司 | 一种盐酸沙丙蝶呤片剂及其制备方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5925323A (ja) | 1982-03-03 | 1984-02-09 | 鐘淵化学工業株式会社 | プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤 |
| DE69526918T2 (de) | 1994-08-05 | 2002-12-19 | Suntory Ltd., Osaka | Arzneimittel gegen spinocerebellare degeneration |
| JP2002515965A (ja) | 1995-08-18 | 2002-05-28 | ダブリュー． ランドリ，ドナルド | 抗体触媒反応の調節による有機化合物の検出 |
| US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
| FR2859996B1 (fr) | 2003-09-19 | 2006-02-03 | Aventis Pharma Sa | Solvat acetonique du dimethoxy docetaxel et son procede de preparation |
| KR20060120147A (ko) | 2003-10-31 | 2006-11-24 | 알타나 파마 아게 | 호흡 질환의 치료를 위한 ｂｈ4의 용도 |
| RU2434870C2 (ru) | 2003-11-17 | 2011-11-27 | Мерк Эпрова Аг | Кристаллические формы дигидрохлорида (6r)-l-эритро-тетрагидробиоптерина |
| CA2545584C (en) * | 2003-11-17 | 2012-10-23 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of metabolic disorders |
| WO2005049614A2 (en) | 2003-11-17 | 2005-06-02 | Biomarin Pharmaceutical Inc. | Processes for preparing tetrahydrobiopterin, and analogs of tetrahydrobiopterin |
| KR20070084270A (ko) | 2004-11-17 | 2007-08-24 | 바이오마린 파머수티컬 인크. | 안정한 정제 제형물 |
| CA2588994A1 (en) | 2004-12-08 | 2006-06-15 | Biomarin Pharmaceutical Inc. | Methods and compositions for the treatment of pulmonary hypertension of the newborn |
| ATE423764T1 (de) | 2005-04-28 | 2009-03-15 | Shiratori Pharm | Verfahren zur herstellung von hydrazon-derivaten |
| US20080075666A1 (en) | 2006-08-25 | 2008-03-27 | Dudley Samuel C Jr | Methods and compositions for treating diastolic dysfunction |
| EP2139485B1 (en) | 2007-04-11 | 2012-10-17 | BioMarin Pharmaceutical Inc. | Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring |
| CL2009000547A1 (es) | 2008-03-10 | 2010-05-07 | Takeda Pharmaceuticals Co | Forma cristalina de (r)-2[[[3-metil-4-(2,2,2-trifluoroetoxi)-2-piridinil]metil]sulfinil]-1h-bencimidazol, metodo de preparacion; composicion farmaceutica y su uso para la profilaxis o tratamiento de ulcera peptica, gastritis, esofagitis erosiva, esofago de barret,dispepsia funcional, cancer gastrico. |
| PL2309983T3 (pl) * | 2008-08-12 | 2019-09-30 | Orpha Swiss Gmbh | Farmaceutyczna postać podawania zawierająca tetrahydrobiopterynę |
| EP2382216A1 (en) | 2008-12-23 | 2011-11-02 | Boehringer Ingelheim International GmbH | Salt forms of organic compound |
| JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
| EP2562176B1 (en) | 2010-04-22 | 2018-08-15 | Nihon University | Medicinal agent and beverage/food for preventing cerebral dysfunction and improving same |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| CN103458900A (zh) | 2011-03-01 | 2013-12-18 | 鲁必康研究私人有限公司 | 四氢生物蝶呤的稳定组合物 |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| ES2681345T3 (es) * | 2012-05-07 | 2018-09-12 | Shiratori Pharmaceutical Co., Ltd. | Método para producir sepiapterina y tetrahidrolactoilpterina |
| EP3468534A4 (en) | 2016-06-13 | 2020-02-05 | Meharry Medical College | MODULATION OF THE NITRIC OXIDE SYNTHASE PATHWAY FOR ORAL HEALTH |
| WO2018019931A1 (en) | 2016-07-29 | 2018-02-01 | Dipharma S.A. | Pharmaceutical composition kit comprising sapropterin dihydrochloride |
| TWI765936B (zh) | 2016-11-29 | 2022-06-01 | 美商東京威力科創Ｆｓｉ股份有限公司 | 用以對處理腔室中之微電子基板進行處理的平移與旋轉夾頭 |
| KR102561697B1 (ko) | 2016-11-29 | 2023-07-28 | 피티씨 테라퓨틱스 엠피, 인크. | 세피아프테린의 다형체 및 그의 염 |
| US11130760B2 (en) | 2016-11-29 | 2021-09-28 | Ptc Therapeutics Mp, Inc. | Polymorphic form of sepiapterin |
| JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
| MX2020002271A (es) | 2017-09-01 | 2020-10-05 | Ptc Therapeutics Mp Inc | Composiciones farmaceuticas que comprenden sepiapterina y sus usos de las mismas. |
| CN112654356A (zh) | 2018-05-30 | 2021-04-13 | Ptc医疗Mp公司 | 增加四氢生物蝶呤血浆暴露的组合物和方法 |
| BR112020024332A2 (pt) | 2018-05-30 | 2021-02-23 | Ptc Therapeutics Mp, Inc. | sais farmaceuticamente aceitáveis de sepiapterina |
| SMT202400430T1 (it) | 2018-05-30 | 2024-11-15 | Ptc Therapeutics Mp Inc | Somministrazione di sepiapterina, senza alcun alimento, per uso in un metodo per incrementare l’esposizione plasmatica di sepiapterina |
| ES2994060T3 (en) | 2019-08-05 | 2025-01-16 | Ptc Therapeutics Mp Inc | Use of sepiapterin and metabolites thereof to treat radiation exposure |
| PT4034122T (pt) | 2019-09-25 | 2025-09-18 | Ptc Therapeutics Mp Inc | Métodos de tratamento de hiperfenilalaninemia |
-
2017
- 2017-11-28 KR KR1020197015403A patent/KR102561697B1/ko active Active
- 2017-11-28 MX MX2019006206A patent/MX386520B/es unknown
- 2017-11-28 EP EP17876202.7A patent/EP3548497A4/en active Pending
- 2017-11-28 KR KR1020257010115A patent/KR20250051124A/ko active Pending
- 2017-11-28 IL IL301470A patent/IL301470A/en unknown
- 2017-11-28 CN CN201780084821.XA patent/CN110248948B/zh active Active
- 2017-11-28 CN CN202310843616.4A patent/CN116903624A/zh active Pending
- 2017-11-28 KR KR1020237025450A patent/KR102789662B1/ko active Active
- 2017-11-28 JP JP2019548534A patent/JP7148533B2/ja active Active
- 2017-11-28 WO PCT/US2017/063517 patent/WO2018102315A1/en active Application Filing
- 2017-11-28 MA MA046973A patent/MA46973A/fr unknown
- 2017-11-28 BR BR122021026889A patent/BR122021026889A8/pt not_active Application Discontinuation
- 2017-11-28 US US16/464,771 patent/US11072614B2/en active Active
- 2017-11-28 IL IL266955A patent/IL266955B2/en unknown
- 2017-11-28 CA CA3043502A patent/CA3043502A1/en active Pending
- 2017-11-28 AU AU2017366879A patent/AU2017366879C1/en active Active
-
2019
- 2019-05-28 MX MX2021011683A patent/MX2021011683A/es unknown
- 2019-05-28 MX MX2021011676A patent/MX2021011676A/es unknown
- 2019-06-10 CO CONC2019/0006018A patent/CO2019006018A2/es unknown
-
2021
- 2021-06-09 US US17/342,910 patent/US11773097B2/en active Active
-
2022
- 2022-05-23 AU AU2022203481A patent/AU2022203481B2/en active Active
- 2022-09-22 JP JP2022151886A patent/JP2023002532A/ja active Pending
-
2023
- 2023-08-21 US US18/236,095 patent/US12269829B2/en active Active
-
2024
- 2024-01-18 AU AU2024200344A patent/AU2024200344A1/en active Pending
- 2024-05-30 JP JP2024087740A patent/JP2024123011A/ja active Pending
-
2025
- 2025-01-15 US US19/021,475 patent/US20250230164A1/en active Pending
Also Published As
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: CENSA PHARMACEUTICALS INC. (US) Free format text: A FIM DE ATENDER A ALTERACAO DE NOME REQUERIDA ATRAVES DA PETICAO NO 870220040140, DE 09/05/2022, E NECESSARIO APRESENTAR A TRADUCAO JURAMENTADA DO DOCUMENTO, ALEM DA GUIA DE CUMPRIMENTO DE EXIGENCIA. |
|
| B25D | Requested change of name of applicant approved |
Owner name: PTC THERAPEUTICS MP, INC. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: PTC THERAPEUTICS MP, INC. (US) |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |